Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes

BACKGROUND: Targeted drugs have greatly improved the therapeutic outcome of non‐small cell lung cancer (NSCLC) patients compared with conventional chemotherapy, whereas about one‐third of patients are so far not suitable for targeted therapy due to lack of known driver oncogenes such as a mutated re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qianqian, Li, Jun, Zhu, Jing, Mao, Jiaqi, Duan, Chao, Liang, Xiao, Zhu, Lingyun, Zhu, Mengyan, Zhang, Zhihong, Lin, Fan, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189421/
https://www.ncbi.nlm.nih.gov/pubmed/35692096
http://dx.doi.org/10.1002/ctm2.882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189421/
https://www.ncbi.nlm.nih.gov/pubmed/35692096
http://dx.doi.org/10.1002/ctm2.882

Ejemplares similares